PROjEN and Axion Form Strategic Alliance
News Apr 15, 2010
PROjEN PLC has joined forces with Axion Group in a strategic partnership to develop business opportunities in the biofuels, advanced thermal waste processing, specialty chemicals and mineral processing sectors.
PROjEN's joint venture with Axion, the UK's specialist in innovative resource recovery, brings together the complementary skills of two highly-experienced and professional consulting companies, as well as providing both firms with exciting possibilities for growth.
Through this alliance, clients can access a broader portfolio of expertise that combines PROjEN's project management strengths with Axion's strong process design and development capabilities.
The two companies forged links several years ago when Axion helped Greenergy Biofuels to select PROjEN as its preferred supplier of project management services for its fuel storage facilities and large-scale biodiesel production plant.
PROjEN's Managing Director Martin Seabrook comments.. "At PROjEN we have a set of values and culture that we all share. Our success has been built on working closely with our clients and by "doing what we say we will do". As such it is vital that when we align ourselves with a partner they must share our business ethos. After many years of working with Axion on an informal basis it became totally logical to progress to a more collaborative way of working".
Axion's director Roger Morton says the collaboration brings benefits to the clients of both businesses with the ability to offer a wider range of specialist skills, best practice business processes and increased resources - particularly for larger or more complex projects.
"We have complementary skills, therefore it made perfect sense to develop this strategic alliance in carefully defined areas with PROjEN; a company we already know well and trust through our existing work," says Roger.
Massachusetts General Hospital (MGH) researchers have found that extracellular RNA (exRNA) in urine may be a source of biomarkers for the two most common forms of muscular dystrophy, noninvasively providing information about whether therapeutic drugs are having the desired effects on a molecular level.READ MORE